It has been recently reported that the use of broad-spectrum antibiotics shortly before or after the initiation of PD-1/PD-L1 blockade can be associated with poor clinical outcome in cancer patients [148], thus indicating that the microbiota plays a central role in the cancer immunosurveillance [149]. This evidence concerns the gene CD274 and cancer.